Non Muscle Invasive Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Non Muscle Invasive clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 34 trials

Recruiting
Phase 1

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Non Muscle Invasive Bladder Cancer
Pfizer294 enrolled53 locationsNCT07206225
Recruiting
Phase 1Phase 2

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled10 locationsNCT05710848
Recruiting
Phase 1Phase 2

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 2

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
John Sfakianos60 enrolled3 locationsNCT06503614
Recruiting
Not Applicable

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Istituto Oncologico Veneto IRCCS200 enrolled9 locationsNCT06245603
Recruiting
Phase 2

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled8 locationsNCT05796375
Recruiting
Phase 2

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled61 locationsNCT05951179
Recruiting
Phase 2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled15 locationsNCT07283835
Recruiting
Phase 4

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Non Muscle Invasive Bladder CancerHigh Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza327 enrolled1 locationNCT05962541
Recruiting
Phase 2

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
CHU de Quebec-Universite Laval160 enrolled7 locationsNCT05327647
Recruiting
Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Urothelial Carcinoma BladderNon Muscle Invasive Bladder CancerNMIBC+4 more
Aura Biosciences55 enrolled17 locationsNCT05483868
Recruiting

Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG

Non Muscle Invasive Bladder Cancer
Johns Hopkins University42 enrolled1 locationNCT05672615
Recruiting
Phase 3

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center125 enrolled1 locationNCT06929286
Recruiting
Phase 1Phase 2

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Phase 4

Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Jakob Kristian Jakobsen272 enrolled8 locationsNCT06781879
Recruiting
Phase 1

A Phase I Intravesical PPM Therapy for NMIBC

Non Muscle Invasive Bladder Cancer
VA Office of Research and Development29 enrolled1 locationNCT05519241
Recruiting
Phase 1

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

Non Muscle Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center55 enrolled7 locationsNCT05126472
Recruiting

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

Non Muscle Invasive Bladder Cancer
University of Texas Southwestern Medical Center600 enrolled2 locationsNCT05825950
Recruiting
Not Applicable

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT07036731
Recruiting
Phase 2

Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

Non Muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc.70 enrolled1 locationNCT06663137